Selectis Health Posts $1.90 EPS from Asset Sales, Core Revenue Plunges 30%
GBCS has more than doubled off its 52-week low of $0.405 on elevated volume (2.0× avg).
Summary
Selectis Health reported Q1 2026 revenue of $7.29 million, a 30.5% year-over-year decline, but posted a net income of $6.52 million and $1.90 diluted EPS. This positive net income was primarily driven by gains from the sale of skilled nursing facilities, which also reduced debt and improved liquidity. Despite these asset disposals, the company continues to face a working capital deficiency and an ongoing going-concern risk. This follows a period of significant corporate changes, including recent facility sales, a terminated tender offer, and a CEO resignation.
At the time of this announcement, GBCS was trading at $2.97 on OTC in the Life Sciences sector, with a market capitalization of approximately $9.1M. The 52-week trading range was $0.41 to $6.25. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.